CRISPR Therapeutics (CRSP) Tops Q3 EPS by 9c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q3 EPS of ($1.17), $0.09 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $890 thousand versus the consensus estimate of $9.41 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance
• EquipmentShare.com Inc. (EQPT) Reports Q2 EPS of $0.18; Offers Guidance
• ArriVent BioPharma, Inc. (AVBP) Misses Q2 EPS by 13c